JP2016527202A - 癌の治療方法 - Google Patents

癌の治療方法 Download PDF

Info

Publication number
JP2016527202A
JP2016527202A JP2016519586A JP2016519586A JP2016527202A JP 2016527202 A JP2016527202 A JP 2016527202A JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016519586 A JP2016519586 A JP 2016519586A JP 2016527202 A JP2016527202 A JP 2016527202A
Authority
JP
Japan
Prior art keywords
cancer
amount
compound
tumor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527202A5 (enExample
Inventor
ダニエル ピー． ブラッドリー，
ダニエル ピー． ブラッドリー，
ロビー ジェイ． ロバートソン，
ロビー ジェイ． ロバートソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2016527202A publication Critical patent/JP2016527202A/ja
Publication of JP2016527202A5 publication Critical patent/JP2016527202A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
JP2016519586A 2013-06-10 2014-06-10 癌の治療方法 Pending JP2016527202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833186P 2013-06-10 2013-06-10
US61/833,186 2013-06-10
PCT/US2014/041643 WO2014200969A2 (en) 2013-06-10 2014-06-10 Methods of treatment of cancer

Publications (2)

Publication Number Publication Date
JP2016527202A true JP2016527202A (ja) 2016-09-08
JP2016527202A5 JP2016527202A5 (enExample) 2017-07-20

Family

ID=52022914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016519586A Pending JP2016527202A (ja) 2013-06-10 2014-06-10 癌の治療方法

Country Status (4)

Country Link
US (1) US20170035917A1 (enExample)
EP (1) EP3008212A4 (enExample)
JP (1) JP2016527202A (enExample)
WO (1) WO2014200969A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534234A (ja) * 2018-08-09 2021-12-09 シャンドン ハブル キセン バイオロジカル テクノロジー カンパニー リミテッド 多機能標的免疫小分子抗癌薬のクエン酸ベスタゾミブおよびその製造方法と使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924597A1 (en) 2013-09-19 2015-03-26 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
US20180078599A1 (en) * 2015-03-27 2018-03-22 The Research Foundation For The State University Of New York Methods and materials for treating cancer
AU2016243516A1 (en) 2015-03-27 2017-11-09 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US12287389B1 (en) * 2015-07-31 2025-04-29 Fonar Corporation Method and system for monitoring effectiveness of a treatment regimen
EP3548515A1 (en) 2016-12-01 2019-10-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
CA3070796A1 (en) 2017-07-24 2019-01-31 Regeneron Pharmaceuticals, Inc. Anti-cd8 antibodies and uses thereof
WO2019213024A1 (en) * 2018-04-30 2019-11-07 Integral Molecular, Inc. Glucose transporter 4 antibodies, methods of making the same, and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524903A (ja) * 2008-06-17 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ボロン酸エステル化合物およびその医薬組成物
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2012040138A2 (en) * 2010-09-21 2012-03-29 Ge Healthcare Limited Novel radiotracer
WO2012075679A1 (en) * 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
WO2013033396A2 (en) * 2011-08-30 2013-03-07 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
JP2013510093A (ja) * 2009-11-05 2013-03-21 ジェネンテック， インコーポレイテッド ジルコニウム放射性標識化システイン改変抗体コンジュゲート
WO2013071142A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028907A1 (en) * 2011-08-23 2013-02-28 Infinity Pharmaceuticals, Inc. Biomarkers predictive of therapeutic responsiveness to hsp90 inhibitors and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524903A (ja) * 2008-06-17 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ボロン酸エステル化合物およびその医薬組成物
JP2013510093A (ja) * 2009-11-05 2013-03-21 ジェネンテック， インコーポレイテッド ジルコニウム放射性標識化システイン改変抗体コンジュゲート
WO2012027379A2 (en) * 2010-08-24 2012-03-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2012040138A2 (en) * 2010-09-21 2012-03-29 Ge Healthcare Limited Novel radiotracer
WO2012075679A1 (en) * 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
WO2013033396A2 (en) * 2011-08-30 2013-03-07 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
WO2013071142A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RADIOISOTOPES, vol. 58, JPN6018010855, 2009, pages 837 - 846, ISSN: 0003900217 *
医学のあゆみ, vol. 242, no. 13, JPN6018010858, 2012, pages 1152 - 1156, ISSN: 0003900218 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534234A (ja) * 2018-08-09 2021-12-09 シャンドン ハブル キセン バイオロジカル テクノロジー カンパニー リミテッド 多機能標的免疫小分子抗癌薬のクエン酸ベスタゾミブおよびその製造方法と使用
JP7215774B2 (ja) 2018-08-09 2023-01-31 シャンドン ハブル キセン バイオロジカル テクノロジー カンパニー リミテッド 多機能標的免疫小分子抗癌薬のクエン酸ベスタゾミブおよびその製造方法と使用

Also Published As

Publication number Publication date
WO2014200969A2 (en) 2014-12-18
EP3008212A4 (en) 2017-05-24
EP3008212A2 (en) 2016-04-20
WO2014200969A9 (en) 2015-05-07
WO2014200969A3 (en) 2015-03-19
US20170035917A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
JP2016527202A (ja) 癌の治療方法
Chapiro et al. Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer
JP6215235B2 (ja) 癌の治療方法
Ruehle et al. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation
Henry et al. ERK inhibition improves anti–PD-L1 immune checkpoint blockade in preclinical pancreatic ductal adenocarcinoma
Zhao et al. Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo
JP6215234B2 (ja) 鼻咽頭癌の治療方法
JP6755457B2 (ja) 合成アミノ酸の癌細胞内取り込みを保持する修飾法と正常細胞を保護する中性子捕捉療法
Shiau et al. Detecting parathyroid adenoma using technetium-99m tetrofosmin: comparison with P-glycoprotein and multidrug resistance related protein expression—a preliminary report
KR20200125581A (ko) 암 진단에서 방사성표지된 프로가스트린
WO2018226971A1 (en) Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
Yang et al. 18F-/68Ga-Labeled Peptide-Based Probes for PET Imaging of ROR1 Expression
Haokun Promotes Therapeutic Efficacy in the Model of Murine Triple Positive Breast
TW202241450A (zh) 放射性標記的αｖβ３及／或αｖβ５整合素拮抗物的醫藥組合物的用途及使用其之方法
Lim et al. The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma
KR20230066651A (ko) 단기-작용성 항혈관신생 제제의 타이밍을 맞춘 투여를 통한 asm아제/세라마이드 경로의 활성화에 의한 화학요법에 대한 종양 반응의 향상
Zhang et al. Aggressive Prolactin-Secreting Pituitary Adenomas and Carcinomas
JP2024537766A (ja) Ｃｃｋ２－ｒを標的とする化合物による治療および／またはイメージングに対する癌と診断された患者の応答を予測する方法、ならびに癌を選択的に治療および／またはイメージングする方法に使用する化合物
Larson Cancer Biology of Molecular Imaging
Dienstmann et al. First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors
Sasaki Ryota Tamura, Toshihide Tanaka, Keisuke Miyake, Kazunari Yoshida &
Zhang et al. PET imaging of VCAM-1 expression and monitoring therapy response in tumor with a 68Ga-labeled single chain variable fragment
HK1205254B (en) Methods of treatment of cancer
MOROZ PRECLINICAL TESTING OF NEW MODALITIES FOR PET VISUALIZATION AND TREATMENT OF RAS-DRIVEN CANCERS
HK40046118A (en) Combination treatment of chemoresistant cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181018